Latest news with #sevasemten
Business Wire
19-07-2025
- Business
- Business Wire
EWTX Investors Have Opportunity to Join Edgewise Therapeutics, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Edgewise Therapeutics, Inc. ('Edgewise' or 'the Company') (NASDAQ: EWTX) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Edgewise reported data from the clinical trials on its drug candidate sevasemten on June 26, 2025. The Company claimed the results were positive but also disclosed that the FDA had "deemed the CANYON data alone insufficient for an accelerated approval." Based on this news, shared of Edgewise fell by 8.86% on the same day. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Yahoo
05-07-2025
- Business
- Yahoo
Edgewise Therapeutics Reports Positive Results for Muscular Dystrophy Treatment
Edgewise Therapeutics Inc. (NASDAQ:EWTX) is one of the best up and coming stocks to invest in now. On June 26, Edgewise Therapeutics announced positive results from its sevasemten program for Becker and Duchenne muscular dystrophies. For Becker muscular dystrophy, the company reported positive data from MESA, which is an open-label extension trial that provides continued access to sevasemten for participants previously enrolled in ARCH, CANYON, GRAND CANYON, or DUNE trials. Sevasemten maintained a favorable safety profile over up to 3 years of treatment. For Duchenne muscular dystrophy, Edgewise announced encouraging topline data from its Phase 2 LYNX and FOX trials. A scientist in a lab coat using a microscope to study a cultured biopharmaceutical product. Sevasemten is an orally administered and first-in-class fast skeletal myosin inhibitor designed to protect against contraction-induced muscle damage in muscular dystrophies like Becker and Duchenne. Becker muscular dystrophy is a rare, genetic, debilitating, and degenerative neuromuscular disorder primarily affecting males, with no currently approved therapies. Duchenne muscular dystrophy is a severe degenerative muscle disorder, the most common type of muscular dystrophy, with a median life expectancy of around 30 years. Edgewise Therapeutics Inc. (NASDAQ:EWTX) is a biopharmaceutical company that discovers, develops, and commercializes therapies for the treatment of muscle disorders. While we acknowledge the potential of EWTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
28-06-2025
- Business
- Yahoo
Edgewise Therapeutics price target lowered to $35 from $40 at Wedbush
Wedbush analyst Laura Chico lowered the firm's price target on Edgewise Therapeutics (EWTX) to $35 from $40 and keeps an Outperform rating on the shares. Edgewise said the FDA has deemed CANYON data insufficient to support an accelerated filing for sevasemten in Becker muscular dystrophy, but the company will explore additional avenues to speed the process, and will seek full approval with GRAND CANYON, the analyst tells investors in a research note. Wedbush still sees several unanswered questions for sevasemten in DMD such as the patient population to be studied, the firm says. Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See today's best-performing stocks on TipRanks >> Read More on EWTX: Disclaimer & DisclosureReport an Issue Edgewise Therapeutics Announces Positive Sevasemten Results Morning Movers: Shell ticks higher after denying interest in BP deal Edgewise update in line with expectations, says Leerink Truist sees 'slight weakness' for Edgewise Therapeutics on regulatory feedback Promising Developments in Edgewise Therapeutics: A Buying Opportunity Amidst Regulatory Challenges Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
